Share
9,819 Posts.
lightbulb Created with Sketch. 1249
clock Created with Sketch. 30/10/23
10:38
Share
Originally posted by Gan_Gans:
↑
Can you please enlighten us on some of the conversations regarding partnerships for OA and MPS? Paul - So let's start with MPS. I should also let investors know that given the likelihood, and again we don't know at this stage because it's double blinded placebo control, but the likely positive outcome for MPS VI in Brazil will also be a adequately sized well-controlled clinical study phase 2 study which meets the criteria for provisional approval in Australia so we will be concurrently trying to get provisional approval for PPS for treating MPS VI patients in Australia and that most certainly can be managed by Paradigm because the number of sufferers in Australia is much smaller market than the osteoarthritis market. But in terms of discussions, in relation to MPS, we have been targeting companies in three geographic hotspots. So it's ultra rare but in some countries there are higher proportions of these subjects relative to the rest of the world, areas such as Latin America particularly Brazil, which is why we did that phase 2 study there, also the Middle East and North Africa is a considerable hotspot and also Turkey and Germany is the third area. So we have a commercial partner in Europe who is looking to transact with the company on the asset for Turkey/Europe.
Expand
MENA and LATIN Amercia are two core regions for MPS
(20min delay)